Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLYTE vs SOMA COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: management of muscle spasms, tension headaches
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Carisoprodol: approximately 2-4 hours in adults with normal renal function. Meprobamate: approximately 10-12 hours. The prolonged half-life of meprobamate contributes to accumulation with repeated dosing, especially in elderly or renally impaired patients, leading to increased risk of sedation and dependence.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite); aspirin is hydrolyzed to salicylic acid via esterases in the liver and plasma.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Carisoprodol and its active metabolite meprobamate are primarily excreted renally. Approximately 60% of a dose is eliminated as unchanged carisoprodol and meprobamate in urine, with the remainder as various hydroxylated metabolites. Less than 1% is eliminated in feces. Meprobamate undergoes hepatic metabolism, and about 10-20% is excreted unchanged in urine.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Carisoprodol: approximately 60% bound to plasma proteins, primarily albumin. Meprobamate: approximately 15-25% bound to plasma proteins.
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Carisoprodol: Vd approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Meprobamate: Vd about 0.7 L/kg.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Oral: Carisoprodol is well absorbed with bioavailability >90%. The absorption rate may be slightly reduced with food, but extent is not significantly affected.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
Cr Cl <30 m L/min: avoid use due to aspirin component; Cr Cl 30-50 m L/min: reduce dose or extend interval; monitor for carisoprodol accumulation.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Not recommended for children under 12 years; safety and efficacy not established.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Initiate at lowest dose (1 tablet); avoid use in patients with Cr Cl <30 m L/min; monitor for CNS depression and bleeding risk.
None
No FDA black box warning.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Dependence and withdrawal: Carisoprodol can cause dependence, abuse, and withdrawal symptoms after prolonged use,Sedation: May impair mental or physical abilities; caution with driving or operating machinery,Bleeding risk: Aspirin component increases risk of bleeding, especially with alcohol, anticoagulants, or existing bleeding disorders,Hypersensitivity: Allergic reactions including anaphylaxis can occur
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
History of acute intermittent porphyria,Hypersensitivity to carisoprodol, meprobamate, aspirin, or any component,Severe hepatic or renal impairment,Gastrointestinal bleeding or peptic ulcer disease (active),Children with viral infections (Reye's syndrome risk),Third trimester of pregnancy (aspirin component)
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
Avoid alcohol. Aspirin may cause gastrointestinal irritation; take with food or a full glass of water to reduce risk. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin component (if present in compound) is associated with increased risk of neural tube defects and fetal hemorrhage if used in third trimester. Avoid use during pregnancy unless benefit outweighs risk.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
Carisoprodol and its active metabolite meprobamate are excreted in breast milk. M/P ratio not well established. Concentrations may reach clinical significance. Potential for infant sedation, hypotonia, or withdrawal. Avoid breastfeeding while on this medication.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
No established dosing adjustments for pregnancy. Due to increased renal clearance during pregnancy, consider that standard doses may be less effective. However, lack of safety data generally contraindicates use. If absolutely necessary, use lowest effective dose for shortest duration.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Soma Compound contains carisoprodol (a centrally acting muscle relaxant) and aspirin (an NSAID). Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with a history of substance abuse, porphyria, or G6PD deficiency. Monitor for signs of CNS depression, especially when combined with alcohol or other sedatives. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or those on anticoagulants. Do not use in children or adolescents with viral infections due to risk of Reye's syndrome.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
Take exactly as prescribed; do not increase dose or frequency.,Do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report any signs of bleeding (bruising, black stools, blood in urine) or allergic reactions (rash, swelling, difficulty breathing).,Do not use in children or teenagers with chickenpox or flu symptoms due to risk of Reye's syndrome.,This medication may be habit-forming; do not stop abruptly without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLYTE vs SOMA COMPOUND, answered by our medical review team.
COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. SOMA COMPOUND is a Skeletal Muscle Relaxant Combination that works by Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLYTE and SOMA COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. The standard adult dose of SOMA COMPOUND is: 1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLYTE and SOMA COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. SOMA COMPOUND is classified as Category C. Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin com. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.